#generic medical drugs manufacturer india

[livealthbiopharma]

Livealth Biopharma Pvt Ltd is the leading manufacturer and supplier of generic medical drugs and medicines across India.

[justinspoliticalcorner]

Lori Ann Larocco at CNBC:

Billions in trade came to a screeching halt at U.S. East Coast and Gulf Coast ports after members of the International Longshoremen’s Association (ILA) began walking off the job after 12:01 a.m. ET on October 1. The ILA is North America’s largest longshoremen’s union, with roughly 50,000 of its 85,000 members making good on the threat to strike at 14 major ports subject to a just-expired master contract with the United States Maritime Alliance (USMX), and picketing workers beginning to appear at ports. The union and port ownership group failed to reach agreement by midnight on a new contract in a protracted battle over wage increases and use of automation. In a last-ditch effort on Monday to avert a strike that will cause significant harm to the U.S. economy if it is lengthy — at least hundreds of millions of dollars a day at the largest ports like New York/New Jersey — the USMX offered a nearly 50% wage hike over six years, but that was rejected by the ILA, according to a source close to the negotiations. The port ownership group said it hoped the offer would lead to a resumption of collective bargaining.

The 14 ports where preparations for a strike have been underway are Boston, New York/New Jersey, Philadelphia, Wilmington, North Carolina, Baltimore, Norfolk, Charleston, Savannah, Jacksonville, Tampa, Miami, New Orleans, Mobile, and Houston. New York Governor Kathy Hochul said in a statement issued shortly after midnight that “the first large-scale eastern dockworker strike in 47 years began at ports from Maine to Texas, including at the Port Authority of New York and New Jersey. In preparation for this moment, New York has been working around the clock to ensure that our grocery stores and medical facilities have the essential products they need.” Rhetoric from ILA leadership has been aggressive in the weeks leading up to the strike, with ILA president Harold Daggett, who was a union member the last time it went out on strike in 1977, telling rank-and-file members — who unanimously voted to authorize a strike — in a recent video message, “We’ll crush them.” 

[...] The most significant issues would be faced by food and automobile industries, Kamins said, as they rely especially heavily on the ports that will be shut down. While a surge in inflation is highly unlikely even with a longer strike, even a modest reacceleration could create uncertainty and force the Federal Reserve to be more cautious about lowering interest rates, which would weigh on the overall outlook for job growth and investment. A one-week strike could cost the U.S. economy $3.78 billion, according to an analysis by The Conference Board, and cause supply chain slowdowns through mid-November. In all, the ports threatened with strikes handle $3 trillion annually in U.S. annual international trade.

Many industries are preparing for major repercussions. Noushin Shamsili, CEO and president of Nuco Logistics, which specializes in pharmaceutical imports and exports, said the strike comes at a critical time for inventory replenishment for the pharma sector. “Almost all of this industry is just on time,” said Shamsili. “Raw materials are being brought in to complete drug manufacturing. Medical supplies for clinics and hospitals are on these vessels. For a while importers did not bring in a lot of cargo because they were overflowing with supplies post-Covid. Now they have started reordering medical devices, gloves, syringes, and tubing.” Shamsili also said the East Coast ports are a gateway for generic medicine made in India. Approximately 48% of the active pharmaceutical ingredients used in the U.S. are being imported from India. Without these APIs, medications cannot be produced. APIs are also manufactured in Europe, which also use the East Coast ports as U.S. points of entry.

[...] The Biden administration finds itself in a delicate political moment, with the presidential election one month away and President Biden vowing he will not use existing labor law to force union workers back on the job, which is within his powers under the Taft-Hartley Act. The Taft-Hartley Act, passed in 1947, was a revision of U.S. law governing labor relations and union activity that granted a U.S. president the power to suspend a strike for an 80-day “cooling off period” in cases where “national health or safety” are at risk. 

Today begins the strike along East Coast and Gulf Coast ports after International Longshoremen’s Association (ILA) members walked off their jobs.

This strike, depending on how long it lasts, could have a major impact on the elections and the economy.

[madamlaydebug]

“If cannabis were discovered in the Amazon rainforest today, people would be clambering to make as much use as they could of all of the potential benefits of the plant. Unfortunately, it carries with it a long history of being a persecuted plant.” ~ Dr. Donald Abrams, Chief of Hematology Oncology at San Francisco General Hospital

Approximately 106,000 Americans die yearly from prescribed medications, according to the American Medical Association. Even more frightening, preventable medical errors account for a staggering 400,000 deaths in the U.S. each year — and is considered the 3rd leading cause of death. “It’s equivalent to 2,000 commercial jets taking off each year knowing that they don’t have enough fuel to complete their journeys,” notes Peter Edelstein M.D. “Would you allow your spouse to board one of those planes? Your friend? A stranger?”

Good question. Increasingly, people in the West are seeking out treatments that work harmoniously with the body, instead of against it — in other words, they’re walking away from the medical establishment and all its mishaps, mistakes and pharmaceutical drugs. A case in point is cannabis, especially in its raw form.

A Rich History

Marijuana is one of those plants that, to many, conjures visions of Drug Enforcement Administration (DEA) raids and hippies in a drugged-out daze. But it wasn’t always this way.

“The ancient Chinese knew of marijuana’s pain-relieving and mind-altering effects, yet it was not widely employed for its psychoactive properties; instead it was cultivated as hemp for the manufacture of rope and fabric. Likewise, the ancient Greeks and Romans used hemp to make rope and sails. In some other places, however, marijuana’s intoxicating properties became important. In India, for example, the plant was incorporated into religious rituals. During the Middle Ages, its use was common in Arab lands; in 15th-century Iraq it was used to treat epilepsy; in Egypt it was primarily consumed as an inebriant. After Napoleon’s occupation of Egypt, Europeans began using the drug as an intoxicant. During the slave trade, it was transported from Africa to Mexico, the Caribbean and South America. Marijuana gained a following in the U.S. only relatively recently. During the second half of the 19th century and the beginning of the 20th, cannabis was freely available without a prescription for a wide range of ailments, including migraine and ulcers,” Roger A. Nicoll and Bradley N. Alger remind us in Scientific American.

Even American Founding Father Thomas Jefferson declared: “Hemp is of first necessity to the wealth and protection of the country.”

So what happened?

In 1937, the United States Congress decided — against the recommendation of the American Medical Association — to pass the Marijuana Tax Act. The legislation essentially banned the use of marijuana by making it excessively expensive and difficult to secure. It has been downhill ever since. That is, until the last few years where legalization of marijuana has exploded in the U.S., for both recreational and medicinal uses. For our purposes here, we’re going to look at the health benefits of the plant — which are quite impressive.

An Essential Vegetable

“It [cannabis] has captured these molecules that help our bodies regulatory system be more effective. The bottom line is it’s a dietary essential that helps all 210 cell types function more effectively. I don’t even refer to it as medicine anymore, strictly as a dietary essential.”

~ Dr. William L. Courtney

It may be a stretch for some to recognize rawcannabis as the next in-demand superfood, but Dr. Courtney, a physician with extensive medical training who specializes in the dietary uses of cannabis, presents a provocative case.

When you heat or age cannabis, Dr. Courtney believes that you lose 99% of the benefit cannabis provides. In contrast, if you consume it raw, you’ll reap the full value of the plant. Plus, raw cannabis is non-psychoactive, so you won’t experience a high — an important point for those who would like to utilize the healing aspects of cannabis without feeling drugged or off-center. This means you can also consume a much higher amount of health-promoting compounds with raw cannabis juice compared to if it was smoked or extracted as an oil, according to Dr. Courtney.

Terpenes, essential oils found in cannabis which give the plant its unique aroma, are particularly compelling.A study published in the British Journal of Pharmacology states that terpenoids are “pharmacologically versatile: they are lipophilic, interact with cell membranes, neuronal and muscle ion channels, neurotransmitter receptors, G-protein coupled (odorant) receptors, second messenger systems and enzymes.”

The researchers explored the powerful effect terpenes exert in animal tests. Limonene was found to increase serotonin in the prefrontal cortex and dopamine in the hippocampus region of the brain — both of which help fend-offdepression and feelings of stress. Moreover, limonene induces apoptosis (cell death) of breast cancer cells and demonstrated exceptional radical scavenging properties. It’s also remarkably bioavailable, rapidly metabolized and is highly non-toxic and non-sensitizing.

Myrcene is anti-inflammatory and an effective sleep aid, while pinene acts as a bronchodilator and broad spectrum antibiotic — including the destruction of lethal MRSA bacteria. Pinene also curbs inflammation. Linalool is a sedative and anticonvulsant. Caryophyllene is antimalarial, anti-inflammatory and useful in treating duodenal ulcers. Nerolidol inhibits fungal growth and protozoal parasites. Phytol increases GABA expression, resulting in a calming effect. These are just a handful of the 200 varieties of terpenes found in cannabis.

How to Enjoy More Raw Cannabis in Your Life

For a daily dose, Dr. Courtney advises juicing fifteen cannabis leaves and two buds, which is then added to a small amount of fruit or vegetable juice that is consumed throughout the day. If you would like to learn more about juicing cannabis, this article offers tips and suggestions. Keep in mind that juicing improperly may create heat, which will cause THC to form. Jeffrey C. Raber, Ph.D. also recommends having the strain of marijuana you’re using tested at a reliable and accurate lab so you know exactly what you are getting.

Article sources:

www.psychologytoday.com

www.humboldtjustice.com

www.globalhealingcenter.com

www.cannabisinternational.org

www.ncbi.nlm.nih.gov

www.huffingtonpost.com

www.projectcbd.org

[theculturedmarxist]

I can't reblog it for some reason, but regarding a thread about how awful Mao is and how his policies killed a hundred billion people, I think this is significant.

---

DETROIT — Another country that once had an addiction problem—one that lasted for almost 200 years and involved an incredible 25 per cent of its population—is China.

Today China is virtually drug‐free— and the methods the Chinese used to eradicate their addiction problem might well offer methods we could use to achieve the same results.

China was forced into addiction by the Opium Wars. Contrary to popular belief, these wars—from 1839 to 1842 —did not originate because China wanted to export opium. They began when China resisted England's demand to import opium in exchange for Chi nese products—mostly tea, silk, and porcelain. China lost these wars, and among other indignities was forced to exchange its goods for opium. As a result it became a highly narcoticized country, a victim of ruthless Western economic and political policy. By 1850 an entire fifth of the revenue of the British Government of India — the source of opium — came from Chinese consumption of this drug.

Obviously to enlarge the market for opium, China was forced to create a huge number of addicts. And it did.

In October of 1949 the People's Re public of China was proclaimed. With in a year the Communist Government instituted a comprehensive program designed to eliminate this threat to the nation. All evidence indicates that by 1953 the problem of narcotic drug abuse was practically eliminated.

One important factor was the changed ideology of the young people —no new supply of addicts was forth coming. The changes in outlook in cluded a redefinition of the nation and its youth, of their worth and role. In rural areas this new definition was based on land distribution; collective farming; new educational, social, and vocational opportunities; and the elec tion of local councils. In the cities it took the form of nationalization of commerce and industry, full employ ment, worker control, and the end of foreign domination.

This total ideological transformation of the younger generation was accom panied by the reintegration of Chinese society through small street commit tees that offered cultural leadership.

Equally significant in the Chinese drive to eliminate narcotic addiction were its methods of plugging the source, China is 80 per cent rural, and an unknown but significant part of the land had been turned into poppy cul tivation. The first major economic and political mass campaign of the Gov ernment was land reform, and this aim was coordinated with elimination of poppy growth. Distribution of land from large landholders to landless peasants was accompanied by the need to convert the opium cash crops to badly needed food crops. Today China produces enough opium to meet its medical needs, but no more.

Smuggled opium was still a source of the drug, and China acted to stop this supply with a policy of “carrot and stick.” Leniency was recom mended for employes and workers of opium traffickers; but heavy penalties existed for those controlling the traf fic, manufacture, or growth of opium.

China's attitude toward the individ ual reformed addict was one of good willed congratulations, and represents another important reason why the nar cotic problem was overcome. The re habilitation of opium addicts began with their registration. Arrangements by city‐wide antiopium committees for addict rehabilitation included treat ment to break the habit at home, in clinics and in hospitals.

At every stage of personal rehabili tation the ideological motivation was stressed. Given China's attitudes, this ideology was strong on political, so cial, and economic information. But the important thing is that the anti drug campaign recognized that the de sire and will of the addict is ultimately the controlling factor of addiction. China's policy was not simply to de prive a person of drugs, but to replace the need for narcotics with a forceful, national commitment. Equally signifi cant, the former addict was fully ac cepted back into Chinese life without official stigma or prejudice.

Naturally, many questions have to be answered about the total success of the Chinese experience. Is there an addict population living in labor camps or prisons because of failure to re habilitate? Do the rehabilitated addicts all function as useful members of Chi nese society? To what extent would addiction be a problem in China if its internal and border controls were less stringent? Does traditional Chinese medicine offer useful ideas about ad diction treatment?

---

Wikipedia puts the census count in 1950 at 546,815,000, and a quarter of that is 136,703,750. So about that many people saved from opium addiction by the Communists.

I wonder if that's the reason the West wants to focus so much on the famine.

[marketsndata]

India Chromatography Instruments Market Size, Share, Growth and Forecast 2032

India chromatography instruments market is projected to grow at a CAGR of 7.50% from FY2025 to FY2032, increasing from USD 451.23 million in FY2024 to USD 804.76 million by FY2032. The market is anticipated to witness growth in the forecast period due to an increase in the demand for analytical solutions for precise healthcare outcomes. Investment in pharmaceutical research, high regulatory requirements for drug quality, and a focus on advanced diagnostics would drive chromatography adoption in the Indian healthcare sector.

Chromatography plays a significant role in drug delivery. Moreover, chromatographic techniques and equipment have become essential for biotechnological and pharmaceutical companies to develop pure drug molecules. It allows research to separate, analyze, and purify compounds and their mixtures efficiently. As drug development continues to rise in India, more advanced and analytical tools are required to support the entire new drug development process. This will create a demand for chromatography instruments with enhanced capabilities. Many industry leaders strategically partner with other companies to expand their analytical capabilities in India. For instance, in July 2023, Waters Corporation (Waters) acquired Wyatt Technology Corporation (Wyatt), to develop new analytical tools to aid drug processes. The coupling of Waters’ Liquid Chromatography (LC) instrumentation with Wyatt’s light-scattering technology enables Waters India to be more competent in supporting biopharma activities during drug development, manufacture, and quality control processes.

Rising Pharmaceutical R&D Investments to Support Market Expansion

Increased investment in pharmaceutical R&D is further driving the chromatography instruments market in India as demand for high-end analytical equipment increases support in drug development and quality checks. Recent initiatives such as Pharma Vision 2047 and research and development incentives have added pace to the generic drug manufacturing and novel therapeutics business of the Indian pharmaceutical industry. In such a scenario, the thrust now is on stringent regulatory standards, and there is an immense demand for chromatography instruments to study the complex nature of compounds, impurities, and active pharmaceutical ingredients. Investment in R&D between global pharmaceutical companies and Indian firms further intensifies this. As a result, the requirement for sophisticated analytical techniques like chromatography boosts the efficacy and accuracy of drug testing, quality assurance, and formulation processes. Also, in September 2023, to strengthen the research and developmental activities in the pharmaceutical and medical technology sectors, the government of India launched the Pharma and MedTech sector scheme of USD 61 million (INR 5,000 crore). Under this scheme, funding of more than USD 13.41 million (INR 1,100 crore) will be provided to nine pharmaceutical companies to undertake research work. The schemes are expected to collaborate between companies and academic institutions for pharmaceutical innovations.

Technological Advancements to Fuel Market Growth

Technological advancements in the chromatography instruments market are driven by the launch of more accurate, faster, and more sensitive reagents and resins. Advanced techniques, for instance, high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and gas chromatography-mass spectrometry (GC-MS), improve the detection of trace element as well as impurities detection in pharmaceutical, food safety, and environmental testing applications. Further innovations are noticed in automated systems and data integration, streamlining workflows, eliminating human error, and enhancing the efficiency of laboratories. Portable and miniaturized chromatography devices expanded the use of chromatography from typical lab settings to on-site tests. Such developments respond to quality control and regulatory requirements that have become more demanded by India’s industrial sectors. Integrating artificial intelligence (AI) technology into chromatography instrumentation improves lab efficiency and accuracy. For instance, in February 2023, Agilent Technologies, Inc. (Agilent) acquired AI technology developed by Virtual Control. The latter is a company that develops AI and machine learning software, including laboratory analysis. This technology automates complicated processes in chromatography and mass spectrometry data analysis through its software product called ACIES. It increases the speed of work to be executed, from preparation to reporting on samples in a laboratory. Agilent plans to integrate ACIES into the MassHunter LC/MS and GC/MS platforms, wherein the core members of the ACIES team will join Agilent.

High-Performance Liquid Chromatography (HPLC) to Hold Significant Market Share

The segment of high-performance liquid chromatography (HPLC) dominates India chromatography instruments market with a major share based on factors such as precision, versatility, and reliability in various applications. The ability of HPLC to carry out separation, identification, and quantification of complex mixtures makes it important in pharmaceuticals, food safety, and environmental testing. Advanced columns for HPLC are touted as the pursuit of achieving greater analytical accuracy. This pharmaceutical sector has stringent quality control standards, for which HPLC has been made a necessity for testing and validation of drugs. Ultra-high-performance liquid chromatography is a new advancement in this technology that offers faster analysis with lower solvent consumption, propelling the acceptance of the technology even more in the Indian market.

For instance, in May 2023, Anand Milk Union Limited (AMUL) opened the first-ever advanced lab specialized in testing organic food in Gandhinagar, Gujarat. The lab is equipped with advanced technologies, including HPLC, and others, such as Gas Chromatograph-Mass Spectrometer (GC-MS) and Liquid Chromatograph-Mass Spectrometer (LC-MS). These equipment can detect and quantify specific amounts of organic compounds, pesticides, herbicides, etc., in food samples. The lab tests for trace elements, heavy metals, mycotoxins, additives, and preservatives allow organic producers to work together with the best possible testing.

Download Free Sample Report

Future Market Scenario (FY2025 –FY2032F)

The market is expected to experience significant growth in the coming years due to the increased adoption of green chromatography techniques. The technique involves the use of an eco-friendly solvent and waste minimization. Emerging demand for miniaturized and portable chromatography systems for on-site testing of food safety, pharmaceuticals, and environmental monitoring. Artificial intelligence and machine learning analysis are increasingly being used, enhancing the results’ accuracy and speed.

The rising regulatory requirement for quality control in drug development fuels further demands for advanced chromatography solutions, ultimately providing immense market growth opportunities over the next few years. For instance, in January 2024, the Central Drugs Standard Control Organization (CDSCO) Sub Zonal Office and Central Drug Testing Laboratory (CDTL) was established in Indore, Madhya Pradesh. It will work towards strengthening the regulation of drugs, cosmetics, and medical devices in the area to deliver quality medicines in the country. This new CDTL comes with modern capabilities for up-to-date laboratories with 12 HPLC systems, where samples of medicines can be adequately tested and assured of quality.

Report Scope

“India Chromatography Instruments Market Assessment, Opportunities and Forecast, FY2018-FY2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of India chromatography instruments market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between FY2025 and FY2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/india-chromatography-instruments-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[marketingreportz]

Erythropoietin Stimulating Agent Market - Forecast(2024 - 2030)

Erythropoietin Stimulating Agent Market Overview:

Request Sample Report :

Additionally, the growing demand for biosimilars is creating substantial growth opportunities for the Erythropoietin Stimulating Agent (ESA) Market. In 2023, According to Association for Accessible Medicines (AAM) report, the generic and biosimilar drugs contributed a ground-breaking $408 billion in 2022 savings for both American patients and the healthcare system. This significant financial impact reflects the substantial value these medications bring to the erythropoietin stimulating agent (ESA) market emphasizing the growing utilization of biosimilars and generics within the realm of ESA treatments. These savings underscore the pivotal role of cost-effective alternatives in enhancing accessibility to ESA therapies, thereby positively influencing the market landscape by facilitating greater affordability and broader patient access to these crucial treatments. These factors positively influence the Erythropoietin Stimulating Agent industry outlook during the forecast period.

Market Snapshot:

Erythropoietin Stimulating Agent Market — Report Coverage:

The “Erythropoietin Stimulating Agent Market Report — Forecast (2023–2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Erythropoietin Stimulating Agent Market.

North America (U.S., Canada and Mexico)

Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

Rest of the World (Middle East and Africa).

COVID-19 / Ukraine Crisis — Impact Analysis:

The COVID-19 pandemic significantly influenced the Erythropoietin Stimulating Agent (ESA) market, triggering substantial shifts in demand dynamics and operational landscapes. Supply chain disruptions, lockdown measures, and healthcare system strains disrupted ESA manufacturing, distribution, and patient access. Treatment delays and altered healthcare-seeking behaviours impacted ESA usage patterns. Additionally, regulatory challenges and market uncertainties intensified the market’s volatility. However, amidst these challenges, the pandemic highlighted the importance of innovative healthcare solutions, potentially fostering a climate for ESA market recovery and adaptation.

Inquiry Before Buying :

• The Ukraine crisis has injected notable uncertainties into the Erythropoietin Stimulating Agent (ESA) market. Geopolitical tensions and disruptions in the region have reverberated through the global supply chain, affecting ESA manufacturing and distribution. Fluctuations in raw material availability and increased logistical challenges pose risks to market stability. Regulatory complexities further contribute to the impact requiring market stakeholders to navigate evolving compliance landscapes. While challenges persist, strategic adaptations such as diversifying supply sources and robust risk management, become imperative. The crisis underscores the importance of resilience and proactive strategies for ESA market players in mitigating the multifaceted effects of the Ukraine crisis.

Key Takeaways:

• Asia-Pacific Region Register Fastest Growth

Geographically, in the global Erythropoietin Stimulating Agent Market share, Asia Pacific is analyzed to grow with the highest CAGR of 5.1% over the forecast period 2023–2030 owing to expanding healthcare infrastructure, rising chronic disease prevalence and increased awareness of ESA treatments, this region experiences accelerated market growth. Favorable government initiatives and growing healthcare expenditure further fuel the demand for ESAs. With a robust emphasis on innovation and accessibility coupled with a burgeoning patient population, the Asia-Pacific region signifies immense potential for sustained growth and market expansion in the ESA segment. In 2023, According to NCBI Organization Report, they revealed a significant finding pertaining to the use of erythropoietin in haemodialysis patients in India, a conservative ESA dosing regimen corresponds to a 20% decrease in the risk of overall mortality. This finding sheds a positive light on the (ESA) market by supporting a cautious dosing approach that balances the potential risks associated with higher ESA doses against their crucial benefits in correcting anemia.

Schedule A Call :

• Epoetin-Beta to Register the Fastest Growth

In the Erythropoietin Stimulating Agent Market analysis, the Epoetin-Beta segment is estimated to grow with the highest CAGR of 7.2% over the forecast period 2023–2030 owing to its advanced therapeutic efficacy and extended half-life. Its prolonged action and enhanced patient convenience drive its accelerated adoption, particularly in chronic conditions like anemia associated with chronic kidney disease and cancer-related treatments. Coupled with its cost-effectiveness and expanding applications, Epoetin-Beta emerges as a frontrunner, capturing substantial market share and fostering robust growth trends in the ESA segment, aligning with the evolving needs of healthcare providers and patients alike.

• Kidney Disorders is Leading the Market

According to the Erythropoietin Stimulating Agent Market forecast, the Kidney Disorders held the largest market of 32% in 2022 owing to their predominant association with anemia and subsequent high demand for ESA treatments. Conditions like chronic kidney disease (CKD) drive this market, requiring effective management of associated anemia. ESA therapies play a pivotal role in addressing anemia in CKD patients stimulating significant market growth. With a substantial patient population needing ongoing treatment, coupled with increasing awareness and advancements in ESA formulations tailored for renal conditions, kidney disorders maintain a leading position, shaping the trajectory of the ESA market. In 2023, the International Society of Nephrology Association, the ISN-GKHA multinational study on the global burden of kidney disease revealed that among the approximately 850 million individuals impacted by chronic kidney disease (CKD) globally, people from diverse demographics, encompassing various ages and races are affected. These insights underscore the pervasive nature of CKD across diverse populations emphasizing the substantial patient pool requiring treatments like Erythropoietin Stimulating Agents (ESAs).

• The Rising Cancer prevalence is driving the Erythropoietin Stimulating Agent Market

The majority of cancer patients experience anemia, which is anticipated to fuel this segment’s expansion throughout the forecast period. Patients’ features, the type of chemotherapy used, the type and stage of neoplasia, and the severity of the disease are all factors. Fatigue, weakness, and sadness caused by severe anemia, especially in youngsters and the elderly, can significantly lower the quality of life for cancer patients. In 2022, According to the International Agency for Research on Cancer (IARC) worldwide, the incidence of new cancer is predicted to reach 30.2 million by 2040. Patients with cancer are almost invariably found to have severe anemia because the rapidly reproducing cancer cells need a lot of iron for DNA replication, growth, and spreading processes. The erythropoietin stimulating agent market is thus anticipated to expand throughout the projected period due to the rise in cancer patients and chemotherapy treatments.

• Proliferation of Erythropoietin Biosimilars

With an increasing prevalence of cancer-related anemia, there is a growing demand for effective and affordable ESA treatments. Biosimilars, offering comparable efficacy to branded counterparts, are gaining prominence due to their cost-effectiveness. Oncology patients, requiring consistent erythropoiesis stimulation during treatments, find biosimilars a viable option. This trend is steering the ESA market, as healthcare providers and patients alike seek accessible and efficient solutions. The synergy between cancer prevalence and the availability of biosimilar options underscores a transformative phase in the ESA market, emphasizing the critical role of biosimilars in cancer-associated anemia management. In 2022, According National Institutes of Health Organization Biosimilars report, Biosimilars have undergone substantial growth, securing 84 approvals in the EU and 35 in the US, collectively encompassing nearly 90% of the global market. This progression in biosimilar acceptance presents implications for the Erythropoietin Stimulating Agent (ESA) market. These developments in biosimilar affordability and acceptance within the EU signal potential pathways and benchmarks for the ESA market indicating a plausible trajectory for enhanced accessibility, cost-effectiveness and wider utilization of ESA treatments through biosimilar adoption.

Buy Now :

• Side Effects Associated with Erythropoietin Stimulating Agents Hamper Market Growth

Patients taking erythropoietin stimulating substances as medications have been documented to experience several negative effects. These include possible symptoms like fever, swollen joints, high blood pressure, nausea, light-headedness and pain at the injection site. This is anticipated to limit market expansion during the anticipated timeframe. Additionally, reduced patient compliance with treatment may be a result of erythropoietin stimulating agents side effects, that can include high blood pressure, blood clots, and an increased risk of cancer development. The market for erythropoietin stimulating agents medications may be constrained as a result, which may affect the efficacy of the treatment.

For More Details On this report — Request For Sample

Key Market Players:

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Erythropoietin Stimulating Agent Market. The top 10 companies in this industry are listed below:

Amgen Inc.

Johnson & Johnson

F. Hoffmann La Roche Ltd.

Novartis (Sandoz)

Pfizer Inc.

Kyowa Hakko

3S BIO Group

Teva Pharmaceutical Industries Ltd.

Kissei Group

Sanwa Kagaku Kenkyusho

Scope of the Report:

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).

For more Lifesciences and Healthcare Market reports, please click here

[sainorlabs]

Venlafaxine Suppliers in India

India has long been recognized as a global pharmaceutical manufacturing hub, providing high-quality medicines at competitive prices. Among the wide array of pharmaceutical products produced in India, Venlafaxine, an antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class, holds a prominent position. With the increasing demand for mental health treatments worldwide, Indian pharmaceutical companies have stepped up to meet the supply needs for this critical drug.

The Role of Venlafaxine in Mental Health

Venlafaxine is widely prescribed for managing major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. It functions by balancing serotonin and norepinephrine levels in the brain, helping patients improve their mood and mental stability. As awareness about mental health grows, the demand for effective treatments like venlafaxine has surged globally.

India's Contribution to Venlafaxine Production

India has become a trusted source for venlafaxine due to its strong pharmaceutical infrastructure and adherence to global quality standards. Suppliers in India provide venlafaxine in various forms, including:

Tablets (extended and immediate release)

Capsules

API (Active Pharmaceutical Ingredient)

Major Indian pharmaceutical manufacturers, such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Aurobindo Pharma, have developed robust manufacturing and distribution networks, ensuring global availability of venlafaxine.

Key Factors Driving India’s Growth in Venlafaxine Supply

Cost-Effective Production India’s cost-efficient manufacturing processes, combined with access to skilled labor and advanced technologies, allow suppliers to offer venlafaxine at competitive prices without compromising quality.

Regulatory Compliance Indian pharmaceutical companies adhere to international regulatory standards, including certifications from the U.S. FDA, EMA (European Medicines Agency), and WHO-GMP. This ensures that the venlafaxine supplied from India meets stringent safety and efficacy requirements.

Research & Development Indian manufacturers invest heavily in research and development (R&D) to innovate new formulations and improve drug delivery mechanisms, making venlafaxine more effective and patient-friendly.

Export Dominance India accounts for a significant share of the global pharmaceutical export market. Indian venlafaxine suppliers serve markets in the U.S., Europe, Southeast Asia, and Africa, ensuring steady international access to the drug.

Notable Venlafaxine Suppliers in India

Sainor Labs Based in Hyderabad, Sainor Labs is a leading API manufacturer specializing in high-quality venlafaxine. The company emphasizes rigorous quality control and on-time delivery, making it a trusted name in the pharmaceutical supply chain.

Sun Pharma A global leader, Sun Pharma provides venlafaxine formulations for various therapeutic applications, catering to both domestic and international markets.

Aurobindo Pharma Known for its robust API production capabilities, Aurobindo Pharma supplies venlafaxine to several regions worldwide.

Cipla Limited Cipla has a strong foothold in mental health medications, including venlafaxine, offering products with a focus on accessibility and affordability.

Challenges and Opportunities

Despite its advantages, the Indian pharmaceutical industry faces challenges such as fluctuating raw material costs, stringent regulatory scrutiny, and competition from emerging markets. However, these hurdles also present opportunities for Indian suppliers to enhance operational efficiency, adopt innovative manufacturing techniques, and expand their global reach.

Conclusion

India’s venlafaxine suppliers, including prominent names like Sainor Labs, play a pivotal role in addressing the global demand for mental health medications. With a commitment to quality, innovation, and cost-efficiency, these companies are not only driving India’s pharmaceutical growth but also contributing to improved mental health outcomes worldwide.

As the demand for mental health treatments continues to rise, Indian pharmaceutical companies are well-positioned to lead the global venlafaxine supply, ensuring affordable and effective solutions for patients everywhere.

[beaverstrack]

Cefixime USP Manufacturers in India: A Comprehensive Guide

Cefixime USP Manufacturers in India: A Comprehensive Guide

Cefixime, a third-generation cephalosporin antibiotic, is widely used to treat bacterial infections such as respiratory tract infections, urinary tract infections, and ear infections, among others. As one of the most prescribed antibiotics globally, the demand for Cefixime is significant, and India, being a major hub for pharmaceutical manufacturing, plays a crucial role in its production and export.

If you're looking for manufacturers of Cefixime USP (United States Pharmacopeia) in India, it is important to consider companies that comply with global quality standards and hold the necessary certifications for producing pharmaceutical-grade drugs. Below is a guide to some of the top Cefixime USP manufacturers in India.

What is Cefixime USP?

Cefixime USP refers to the formulation of Cefixime that meets the standards set by the United States Pharmacopeia (USP). The USP is a set of quality standards for the preparation, testing, and production of medicines. Products labeled as "USP" indicate that they conform to these rigorous standards, ensuring purity, strength, quality, and consistency.

Leading Manufacturers of Cefixime USP in India

Cipla Limited

Overview: Cipla is one of the leading pharmaceutical companies in India and a prominent global player in the production of antibiotics. The company is known for its high-quality formulations and large-scale manufacturing capabilities, including the production of Cefixime USP.

Key Highlights:

High production standards adhering to GMP (Good Manufacturing Practices).

Well-established global distribution network.

Known for consistent quality and regulatory compliance.

Key Products:

Cefixime Tablets (USP grade).

Cefixime Oral Suspension (USP grade).

Available in different strengths like 200 mg and 400 mg.

Certifications: FDA, WHO-GMP, ISO.

Lupin Pharmaceuticals

Overview: Lupin is another major pharmaceutical manufacturer in India, recognized for producing a wide range of antibiotics, including Cefixime USP. Lupin focuses on high-quality, affordable medications, and it is one of the top exporters of generic drugs worldwide.

Key Highlights:

Strong presence in over 100 countries.

High-quality standards with a focus on R&D.

Compliance with international regulatory standards.

Key Products:

Cefixime 200 mg Tablets.

Cefixime 400 mg Tablets.

Cefixime Oral Suspension.

Certifications: WHO-GMP, FDA, ISO.

Mylan Laboratories

Overview: Mylan, now part of Viatris, is a multinational pharmaceutical company with a significant manufacturing base in India. Mylan produces a variety of generics, including Cefixime USP, and is a major player in both the domestic and international pharmaceutical markets.

Key Highlights:

Manufacturing plants certified by the USFDA, WHO-GMP, and EU.

Strong focus on compliance with international quality and safety standards.

Extensive experience in producing generics for the global market.

Key Products:

Cefixime Tablets (USP grade).

Cefixime Oral Suspension.

Certifications: FDA, WHO-GMP, ISO, EU GMP.

Alkem Laboratories

Overview: Alkem Laboratories is one of India's top pharmaceutical companies, with a strong portfolio of generic antibiotics, including Cefixime USP. Alkem's commitment to quality and its extensive market reach make it a reliable manufacturer for both domestic and international markets.

Key Highlights:

Well-known for its strong market presence in over 50 countries.

Focus on affordable yet high-quality pharmaceutical products.

Research-driven approach for continuous improvement in product development.

Key Products:

Cefixime Tablets (USP grade).

Cefixime Oral Suspension.

Certifications: WHO-GMP, FDA, ISO.

Sun Pharmaceutical Industries Ltd.

Overview: Sun Pharma is one of India's largest pharmaceutical companies, well known for producing a broad range of pharmaceutical products, including antibiotics. Sun Pharma has a robust manufacturing infrastructure and supplies Cefixime USP in various forms to global markets.

Key Highlights:

Leading producer of generic medicines worldwide.

Highly regulated production facilities that meet global quality standards.

Strong R&D investment for continuous improvement.

Key Products:

Cefixime Capsules (USP grade).

Cefixime Oral Suspension.

Certifications: FDA, WHO-GMP, ISO.

Torrent Pharmaceuticals

Overview: Torrent Pharmaceuticals is a well-established pharmaceutical company in India, known for its diverse range of medications. The company produces various antibiotics, including Cefixime USP, ensuring compliance with stringent international regulatory requirements.

Key Highlights:

Strong commitment to high-quality manufacturing.

Active in the production and export of generic medications.

Focus on patient safety and product efficacy.

Key Products:

Cefixime Tablets (USP grade).

Cefixime Oral Suspension (USP grade).

Certifications: WHO-GMP, FDA, ISO.

Aurobindo Pharma

Overview: Aurobindo Pharma is a significant player in the Indian pharmaceutical industry with a strong focus on generic drugs. The company manufactures a variety of antibiotics, including Cefixime USP, and exports to numerous international markets.

Key Highlights:

One of the largest producers of generic drugs worldwide.

Strong infrastructure and advanced technology for manufacturing.

Wide distribution network catering to global demands.

Key Products:

Cefixime Tablets (USP grade).

Cefixime Oral Suspension.

Certifications: FDA, WHO-GMP, ISO.

Key Factors to Consider When Choosing a Cefixime USP Manufacturer in India

When selecting a manufacturer for Cefixime USP, here are some key factors to consider:

Certifications and Compliance: Ensure the manufacturer adheres to global standards like FDA approval, WHO-GMP, ISO, and other regional certifications to guarantee the quality and safety of the product.

Production Capacity: Choose a manufacturer with sufficient production capacity to meet your supply requirements, whether for domestic use or export.

Quality Control: Ensure the manufacturer follows strict quality control processes and provides transparency in testing procedures to guarantee the purity and potency of the Cefixime product.

Experience and Reputation: Opt for manufacturers with a strong track record of producing high-quality pharmaceuticals. This can be confirmed by reviews, customer testimonials, and industry certifications.

Supply Chain and Logistics: If you require bulk quantities, it's essential to assess the manufacturer’s ability to deliver on time, manage large orders, and handle export logistics.

R&D and Innovation: Companies that invest in research and development (R&D) are more likely to provide products with the latest advancements in formulation and delivery mechanisms.

Conclusion

India is home to some of the best manufacturers of Cefixime USP, offering a wide range of antibiotic solutions for global markets. Leading pharmaceutical companies like Cipla, Lupin, Mylan, Alkem, Sun Pharma, Torrent Pharmaceuticals, and Aurobindo Pharma provide top-quality Cefixime products that adhere to international standards. Whether you're a healthcare provider, distributor, or manufacturer, partnering with any of these companies ensures access to reliable, high-quality medications for the treatment of bacterial infections. Always ensure that the selected manufacturer complies with relevant regulatory standards and maintains strict quality control to guarantee the safety and efficacy of the drug.

[livealthbiopharma]

Livealth Biopharma Pvt Ltd is the leading manufacturer and supplier of generic medical drugs and medicines across India.

[tenchlifesciences]

Tenchlife Sciences is Pharmaceutical based Generic Medical Drugs & Medicine Manufacturer & Supplier in India. We are specialized in Pharmaceutical Capsule Manufacturer, supplier and distributor.

[industrynewsupdates]

Pharmaceutical Packaging Market Trends, Opportunities, and Challenges 2024 - 2030

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. A key driver of this growth is the substantial expansion of the pharmaceutical sector itself. In recent years, the pharmaceutical industry has experienced rapid growth, fueled by continuous advancements in science and technology. This upward trend is expected to persist throughout the forecast period, especially in developing countries such as China, India, Saudi Arabia, and Brazil, where the healthcare infrastructure and pharmaceutical demand are expanding quickly.

The United States is the largest pharmaceutical market in the world. Several factors contribute to this dominance, including the size of the healthcare system, high per capita income, and substantial investments in drug development within the country. These elements collectively drive the growth of the pharmaceutical sector in the U.S. Additionally, the increasing importance of generic drugs and broader access to better healthcare services are expected to create further growth opportunities for pharmaceutical packaging in the coming years.

A significant piece of legislation, the 21st Century Cures Act, was signed into law in the U.S. on December 13, 2016. This act is designed to expedite the development of medical products, including pharmaceutical drugs, by enhancing the approval process and encouraging innovation in the industry. The implementation of the Cures Act is expected to spur new developments in pharmaceutical products, which will, in turn, drive the demand for pharmaceutical packaging in the U.S. market. These factors collectively indicate a continued growth trajectory for the pharmaceutical packaging industry, especially in key markets such as the U.S.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Regional Insights

North America

North America dominated the pharmaceutical packaging market with a revenue share of 35.9% in 2023. The largest end-use segment in the region was pharma manufacturing, which includes in-house production of pharmaceutical products. The presence of a substantial number of pharmaceutical plastic bottle manufacturers in the U.S., such as AptarGroup Inc., Gerresheimer AG, Amcor Ltd., and Berry Plastics Group, Inc., is expected to have a positive impact on the demand for pharmaceutical plastic bottles over the forecast period. These companies play a critical role in supplying the packaging materials required for pharmaceutical products, further driving market growth.

Asia Pacific

The Asia Pacific region is anticipated to register the fastest CAGR of over 12% from 2024 to 2030. This growth is driven by increasing health awareness among consumers, particularly in developing countries such as China and India, and rising disposable income levels. As a result, the demand for pharmaceuticals is expected to grow, which will in turn boost the need for pharmaceutical packaging solutions. In 2020, China led the Asia Pacific market and is expected to maintain this position due to government initiatives like Healthy China 2020, as well as a growing aging population and expanding contract-manufacturing activities. These factors contribute to the increasing demand for pharmaceutical packaging in the region.

Europe

In Europe, the pharmaceutical packaging market is expected to experience significant growth due to rising research and development (R&D) activities and the continuous introduction of new medicines aimed at improving patient health and quality of life. Companies such as BioNTech SE and CureVac in Europe have made notable achievements, particularly with their successful vaccine development in 2020. These successes have attracted further investments into the biotech industry in countries like Germany, Russia, and the U.K., propelling the growth of pharmaceutical packaging in the region.

The Saudi Arabian pharmaceutical packaging market is one of the major players in the Middle East & Africa region. International pharmaceutical companies are recognizing the potential of the Middle Eastern and North African (MENA) market. For example, Sanofi is a leading player in Morocco, and GlaxoSmithKline leads the market in Saudi Arabia. In addition, local pharmaceutical companies such as SPIMACO and Hikma from Jordan and Saudi Arabia are aiming to become regional leaders. These developments are expected to drive the demand for various pharmaceutical packaging materials in the region during the forecast period.

Browse through Grand View Research's Plastics, Polymers & Resins Industry Research Reports.

• The global flexible paper packaging market size was estimated at USD 50.35 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2030. 

• The global seaweed packaging market size was valued at USD 699.23 million in 2023 and is expected to expand at a CAGR of 6.6% from 2024 to 2030.

Key Companies & Market Share Insights

The global pharmaceutical packaging market is highly competitive, with numerous players competing for market share. To strengthen their positions, key players are increasingly focusing on acquisitions, which is intensifying the competition within the market. These companies directly compete with each other to secure contracts from large pharmaceutical manufacturers. As a result, the level of competitive rivalry in the market is high.

To differentiate themselves in this competitive landscape, companies are focusing on offering value-added services to attract more clients. Common processes employed by packaging manufacturers to enhance their offerings include spray painting, ultraviolet (UV) coating, and metallization to color packaging containers. Additionally, packaging companies are incorporating various anti-counterfeit measures, such as barcodes, holograms, sealing tapes, and radio frequency identification (RFID) technologies to ensure product authenticity and security.

Notable developments in the market include:

• In November 2023, Amcor Plc, a leading global provider of packaging solutions, announced a Memorandum of Understanding (MOU) with NOVA Chemicals Corporate, a producer of sustainable polyethylene. Under the agreement, Amcor will procure mechanically recycled polyethylene resin (rPE) from NOVA Chemicals for use in the production of flexible packaging films. This partnership supports Amcor’s commitment to sustainable packaging by increasing the use of recycled materials, contributing to the circularity of packaging.

• In July 2023, Constantia Flexibles introduced a new pharmaceutical packaging solution called REGULA CIRC, which uses coldform foil. The packaging replaces conventional PVC with a PE sealing layer, resulting in reduced plastic content and a higher proportion of aluminum. This shift not only enhances the sustainability of the packaging but also improves material recovery during the recycling process.

• In April 2023, Südpack launched its PharmaGuard blister, a new polypropylene-based blister packaging. This product is designed to offer an exceptional water vapor barrier and effective resistance to UV light and oxygen, making it suitable for the packaging of sensitive pharmaceutical products that require enhanced protection.

Key Pharmaceutical Packaging Companies:

• Amcor plc

• Becton, Dickinson, and Company

• AptarGroup, Inc.

• Drug Plastics Group

• Gerresheimer AG

• Schott AG

• Owens Illinois, Inc.

• West Pharmaceutical Services, Inc.

• Berry Global, Inc.

• WestRock Company

• SGD Pharma

• International Paper

• Comar, LLC

• CCL Industries, Inc.

• Vetter Pharma International

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

[omcmedicalblog]

India Medical Device Registration - OMC Medical Limited

Regulatory Authority

Central Drugs Standard Control Organization

The Central Drugs Standard Control Organization (CDSCO) is the National Regulatory Authority (NRA) of India, responsible for regulating drugs and cosmetics under the Drugs & Cosmetics Act, 1940 and rules 1945.

It aims to ensure patient safety, rights, and well-being by ensuring the safety, efficacy, and quality of medical products manufactured, imported, and distributed in the country. CDSCO is responsible for drug approval, clinical trials, setting standards, controlling imported drug quality, and coordinating activities of State Drug Control Organizations.

It also grants licenses for specialized categories of critical drugs such as blood and blood products, I.V. fluids, vaccines, and sera, in collaboration with state regulators. The CDSCO strives for transparency, accountability, and uniformity in its services to ensure the safety, efficacy, and quality of medical products in India.

Link for Regulatory Authority

Local Regulation

Medical Device Act, 2017

Classification of Medical Devices

Class A, B, C and D

Listing or Registration Requirements

A voluntary registration pathway is available to medical devices from April 1, 2020, to October 1, 2021. Medical devices submitted under the new voluntary rules are referred to as “Non-Regulatory Medical Devices.” The registration process will generate a file number the same day which the importer must mention on the label of the medical device prior to placing the devices on the market.

After this voluntary period, all classes of products will need to either have an Import License or register through CDSCO’s online portal.

Class A and B non-Notified medical devices will have 12 months (i.e., by October 1, 2022) to obtain an Import License. Class C and D devices will have 24 months (i.e., by October 1, 2023) to meet the same requirement.

Registration for non-notified medical devices has become mandatory since October 2021.

Starting October 2022, class A & B non-notified devices will become notified devices and hence will require full product registration.

Starting October 2023, class C & D non-notified devices will become notified devices and hence will require full product registration

Documents Required for India Medical Device Registration

Form 40

TR6 Challan

Power of Attorney

Schedule D(I)

ISO 13485 Certificate

Full Quality Assurance Certificate

CE Design Certificate

Declaration of Certificate

Free Sale Certificate

Certificate of Marketability from GHTF countries

Regulatory Approvals

PMS Report

Plant Master File

Device Master File

Registration Timeline

6 to 9 Months

Registration Fee

Fee Details CDSCO

Application fees (online)

Class A: INR 500 (one site); INR 50 (each distinct device)

Class B: INR 1,000 (one site); INR 500 (each device)

Class C and D: INR 5,000 (one site); INR 1,000 (each device)

Application fees (hard copy)

Class A: INR 2,000 (one site); INR 500 (each device)

Class B: INR 5,000 (one site); INR 2,000 (each device)

Class C and D: INR 10,000 (one site); INR 5,000 (each device)

License Validity

Registration certificate (valid for 3 years): Generally, it’s recommended to apply for renewal 6 months before expiry. This ensures enough time for processing and avoids potential interruptions in business operations.

Import license (valid for 5 years): You need to submit the renewal application within 3 months of the expiry date.

Special Labelling Requirements

All the documents must be submitted in English

Additional Comments

Registration for non-notified medical devices has become mandatory since October 2021.

Starting October 2022, class A & B non-notified devices will become notified devices and hence will require full product registration.

Starting October 2023, class C & D non-notified devices will become notified devices and hence will require full product registration

Who should make this Communication?

Manufacturer

Authorized Representative

When to make this Communication?

Before placing a medical device into the market.

Market Access Requirements

Commencing October 1, 2023, the acquisition of an MD-14/15 Import License becomes obligatory for all Class A (Measuring and Sterile), B, C, and D medical devices intended for importation. The MD-14 application procedure mandates the submission of a comprehensive Device Master File (DMF) specific to each product, along with a Plant Master File (PMF) providing details about the manufacturing facility. 

Upon a meticulous approval process, an MD-15 Import License will be issued to a local license holder for the manufacturing site, covering a comprehensive list of all approved medical devices.

As outlined in the Circular (PDF) released on October 12, 2023, it has been specified that non-Notified Class C and D medical devices enlisted in the mandatory registration program, and concurrently undergoing a pending MD-14 application, are granted permission to continue their importation activities for a period of six (6) months.

How OMC Medical can assist you with the Process?

Act as your Authorized representative

Why Choose Us?

Working towards client satisfaction

Cost effective solutions

Project completion before deadline

Quality Regulatory affairs solutions

Contact us for free consultation: info@omcmedical.co.uk

Get more detailed information here: https://omcmedical.com/india-medical-device-registration/

[mysteriouslyelegantpanda]

Pharma Regulatory Consultants: Simplifying Compliance for the Pharmaceutical Industry

The pharmaceutical industry operates under strict regulations to ensure the safety, efficacy, and quality of medicines and healthcare products. Navigating these complex regulatory requirements can be a daunting task for pharmaceutical companies. This is where Pharma Regulatory Consultants come into play, offering specialized expertise to streamline compliance and facilitate market entry.

What Are Pharma Regulatory Consultants?

Pharma regulatory consultants are experts who assist pharmaceutical companies in meeting the legal and regulatory requirements for drug development, approval, manufacturing, and marketing. They provide guidance on domestic and international regulations, helping companies avoid delays and achieve compliance with agencies like the CDSCO in India, FDA in the USA, or EMA in Europe.

Key Services Offered by Pharma Regulatory Consultants

Regulatory Strategy Development

Assessing regulatory requirements based on the target market.

Designing a compliance roadmap for drug approvals.

Regulatory Submissions

Preparing and submitting dossiers, such as Common Technical Documents (CTD) or eCTD, to regulatory bodies.

Managing applications for Investigational New Drugs (IND), New Drug Applications (NDA), or Abbreviated New Drug Applications (ANDA).

Clinical Trial Support

Assisting with clinical trial approvals and ensuring compliance with Good Clinical Practice (GCP) guidelines.

Liaising with ethics committees and regulatory authorities for trial documentation.

Quality Assurance and Audits

Ensuring compliance with Good Manufacturing Practices (GMP) and ISO standards.

Conducting internal audits and preparing for regulatory inspections.

Regulatory Intelligence

Monitoring changes in global pharmaceutical regulations.

Providing insights into new guidelines, trends, or market-specific requirements.

Post-Marketing Compliance

Assisting with pharmacovigilance activities, including adverse event reporting.

Managing lifecycle maintenance, such as renewals, amendments, and labeling updates.

Why Do Companies Need Pharma Regulatory Consultants?

Expertise in Complex Regulations

Regulatory frameworks differ significantly between regions. Consultants possess in-depth knowledge of these complexities, ensuring accurate compliance.

Faster Time-to-Market

With their expertise, consultants minimize errors and delays in submissions, accelerating approval processes.

Cost Efficiency

Avoiding compliance pitfalls and regulatory rejections saves significant resources.

Global Market Access

Consultants help pharmaceutical companies meet international standards, opening doors to global markets.

Industries That Benefit from Pharma Regulatory Consultants

Pharmaceutical Manufacturing: For drug approvals and GMP compliance.

Biotechnology Firms: To navigate biologics and biosimilars regulations.

Medical Device Companies: To meet requirements for combination products.

OTC and Nutraceutical Companies: For compliance with labeling, claims, and advertising standards.

Choosing the Right Pharma Regulatory Consultant

Experience: Look for consultants with proven expertise in your specific domain (e.g., small molecules, biologics, or generics).

Regulatory Knowledge: Ensure familiarity with target market regulations, such as CDSCO, FDA, or EMA requirements.

Client References: Check testimonials or case studies from similar projects.

Proactive Communication: Select a consultant who provides regular updates and clear guidance.

Conclusion

Pharma regulatory consultants are invaluable partners for companies aiming to thrive in a highly regulated industry. From ensuring compliance to streamlining market entry, their expertise helps businesses stay ahead in the competitive pharmaceutical landscape.

Whether you’re a startup developing innovative drugs or an established company expanding globally, a skilled regulatory consultant can make the journey smoother, faster, and more efficient. By partnering with the right consultant, you can focus on delivering quality healthcare solutions while they handle the intricacies of regulatory compliance.

[zenbiotech11]

Active Pharmaceutical Ingredients (API) Manufacturers in India: Bhasya International as a Leading Provider

Active Pharmaceutical Ingredients (API) Manufacturers in India: Bhasya International as a Leading Provider

India has long been a global hub for pharmaceutical manufacturing, playing a vital role in the healthcare industry worldwide. As the third-largest producer of pharmaceuticals by volume and the largest provider of generic medicines, India has earned its reputation as the “pharmacy of the world.” One of the critical components of this success is the production of Active Pharmaceutical Ingredients (APIs). These essential ingredients form the backbone of every pharmaceutical product and are responsible for the therapeutic effect of medications.

In this article, we will explore the importance of API manufacturing in India and highlight Bhasya International as a leading provider in this critical sector.

Understanding Active Pharmaceutical Ingredients (API)

An Active Pharmaceutical Ingredient (API) is the substance in a pharmaceutical drug that is biologically active and produces the intended effect in the body. APIs are combined with other ingredients, such as excipients, to form the final drug product in various forms (tablets, capsules, injections, etc.). The production of APIs involves complex processes and stringent regulations to ensure their efficacy, safety, and quality.

The global demand for APIs has grown substantially in recent years, driven by the increasing prevalence of chronic diseases, the aging population, and greater access to healthcare in emerging markets. As a result, the demand for high-quality, cost-effective APIs is at an all-time high, with India playing a pivotal role in fulfilling this need.

India's Role in the Global API Market

India has emerged as one of the largest producers and exporters of APIs, owing to several factors:

Cost-Effectiveness: The relatively low cost of labor, raw materials, and infrastructure in India makes it a highly competitive destination for API manufacturing.

Skilled Workforce: India has a large pool of skilled professionals in chemistry, pharmaceuticals, and engineering, making it an ideal location for API production.

Regulatory Compliance: India’s API manufacturers comply with stringent regulatory standards set by organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global regulatory bodies.

Infrastructure: With advanced manufacturing facilities and state-of-the-art research and development (R&D) capabilities, Indian manufacturers are well-positioned to meet both domestic and international API demand.

As a result, India produces over 60% of the world’s vaccines and is a key supplier of generic APIs, contributing significantly to global healthcare access.

Bhasya International: A Leading Provider of Active Pharmaceutical Ingredients

Among the many API manufacturers in India, Bhasya International stands out as a leader in the industry. The company has earned a strong reputation for its commitment to quality, innovation, and customer-centric approach in the field of pharmaceutical manufacturing.

What Sets Bhasya International Apart?

Quality Assurance and ComplianceBhasya International adheres to the highest industry standards to ensure the production of APIs that meet the strictest quality requirements. Their manufacturing processes are compliant with Good Manufacturing Practices (GMP), ensuring that every batch of API is safe, effective, and reliable. The company is also certified by major regulatory bodies like the WHO-GMP, ISO, and others, which further bolsters their credibility in the global market.

Extensive Product RangeBhasya International offers a wide range of high-quality APIs across various therapeutic categories, including cardiovascular, anti-diabetic, anti-inflammatory, oncology, and many others. Their extensive portfolio allows them to cater to a diverse set of customer needs, both in India and abroad.

Research and Development (R&D) FocusThe company invests heavily in research and development to stay ahead in an ever-evolving market. Their R&D teams work diligently to develop new APIs, improve existing formulations, and explore cutting-edge technologies to enhance efficiency and reduce production costs. By focusing on innovation, Bhasya International ensures that it can meet the growing demand for high-quality APIs.

Global Reach and PartnershipsBhasya International has successfully expanded its reach beyond India and has established partnerships with pharmaceutical companies worldwide. Through these collaborations, the company has gained access to international markets, further solidifying its position as a leading API manufacturer. Their export network covers regions such as Europe, North America, Asia, and Africa, demonstrating their ability to cater to global demands.

Commitment to SustainabilityAs environmental concerns continue to rise, Bhasya International places a strong emphasis on sustainability. The company has adopted eco-friendly manufacturing processes, implemented waste reduction initiatives, and ensures responsible sourcing of raw materials. This commitment to sustainability reflects the company’s dedication to both the environment and the well-being of future generations.

The Future of API Manufacturing in India

India’s position as a leader in the global API market is expected to continue growing, driven by technological advancements, strong manufacturing capabilities, and increased access to healthcare worldwide. The increasing demand for generic drugs, coupled with the rise in chronic diseases, will continue to fuel the need for high-quality APIs.

As a leading provider of APIs, Bhasya International is well-positioned to take advantage of these market dynamics. With its robust quality assurance systems, diverse product offerings, and dedication to research and development, Bhasya International is set to remain a key player in the global pharmaceutical supply chain.

Conclusion

The importance of Active Pharmaceutical Ingredients (APIs) in modern medicine cannot be overstated, and India’s role in producing and supplying these essential substances has solidified the country as a global leader. Among the many API manufacturers in India, Bhasya International stands as a beacon of quality, innovation, and customer satisfaction.

As the pharmaceutical industry continues to evolve, Bhasya International’s commitment to excellence ensures that it will remain a trusted partner for pharmaceutical companies around the world. With its focus on research, sustainability, and regulatory compliance, Bhasya International is poised to shape the future of API manufacturing for years to come.

If you are looking for a reliable and innovative API manufacturer, Bhasya International offers the experience, expertise, and product range to meet your needs in the ever-growing global pharmaceutical landscape.